Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Jun
30
Today In Oncology
Pooled Analysis of 5-Year Outcomes With Ultra-Hypofractionated SABR in Primary Renal Cell Carcinoma
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
ASCO Remembers Karnofsky Award Recipient Maura Gillison Pioneer in HPV-Associated Cancers
Novel Risk Score Stratifies Major Bleeding Risks in Patients With VTE on DOACs
Long-Term Outcomes With SABR in Primary Kidney Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo